Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 534-542

  Aoki, Nobumasa ^a,b   Tateda, Kazuhiro ^a   Kikuchi, Yoshiaki ^a   Kimura, Soichiro ^a   Miyazaki, Choichiroh ^c   Ishii, Yoshikazu ^a   Tanabe, Yoshinari ^b   Gejyo, Fumitake ^b   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c Miyazaki Pharmacy Ltd   (Japan)

Author keywords

Cytokines; Lipopolysaccharide; Pharmacokinetics; Rifampicin

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; IMIPENEM; LIPOPOLYSACCHARIDE; PIPERACILLIN; PLACEBO; RIFAMPICIN; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; COLISTIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL ANALYSIS;

EID: 60649100857     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn530     Document Type: Article

References (47)

1. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
3. Kollef MH. Ventilator-associated pneumonia - a multivariate analysis. JAMA 1993; 270: 1965-70.
4. Rello J, Ollendorf DA, Oster G et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122: 2115-21.
5. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
6. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003; 51: 347-52.
7. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
8. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
9. Li J, Nation RL, Turnidge JD et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
10. Catchpole CR, Andrews JM, Brenwald N et al. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39: 255-60.
11. Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49: 403-6.
12. Pristovsek P, Kidric J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: An MMR and molecular modeling study. J Med Chem 1999; 42: 4604-13.
13. Warren HS, Kania SA, Siber GR. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob Agents Chemother 1985; 28: 107-12.
14. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162: 328-30.
15. Kwa ALH, Loh CS, Low JGH et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 754-7.
16. Sobieszczyk ME, Furuya EY, Hay CM et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004; 54 566-9.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing - Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
18. Garrod LP, Waterworth PM. Methods of testing combined antibiotic bactericidal action and the significance of the results. J Clin Pathol 1962; 15: 328-38.
19. Timurkaynak F, Can F, Azap OK et al. In vitro activities of nontraditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27: 224-8.
20. Tsuji M, Matsuda H, Miwa H et al. Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: Comparison of in vitro and animal models. J Antimicrob Chemother 2003; 51: 353-9.
21. Tateda K, Takashima K, Miyazaki H et al. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother 1996; 40: 1520-5.
22. Tateda K, Deng JC, Moore TA et al. Hyperoxia mediates acute lung injury and increased lethality in murine Legionella pneumonia: The role of apoptosis. J Immunol 2003; 170: 4209-16.
23. Wise R, Donovan IA, Lockley MR et al. The pharmacokinetics and tissue penetration of imipenem. J Antimicrob Chemother 1986; 18 Suppl E: 93-101.
24. Wolff M, Joly-Guillou ML, Farinotti R et al. In vivo efficacies of combinations of β-lactams, β-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999; 43: 1406-11.
25. Wootton M, Holt HA, Macgowan AP. Development of a novel assay method for colistin sulphomethate. Clin Microbiol Infect 2005; 11: 243-4.
26. Yamaoka K, Tanigawara Y, Nakagawa T et al. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 1981; 4: 879-85.
27. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6: 547-58.
28. Watanabe R, Matsumoto T, Sano G et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 2007; 51: 446-52.
29. Montero A, Ariza J, Corbella X et al. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 1946-52.
30. Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 1085-91.
31. Horianopoulou M, Lambropoulos S, Papafragas E et al. Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J Chemother 2005; 17: 536-8.
32. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of Gram-negative bacilli: Report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12: 315-21.
33. Oie S, Uematsu T, Sawa A et al. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003; 52: 911-4.
34. Erdem I, Kaynar-Tascioglu J, Kaya B et al. The comparison of in the vitro effect of imipenem oF meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Int J Antimicrob Agents 2002; 20: 384-6.
35. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I et al. In vitro interaction of collistin and rifampicin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003; 15: 235-8.
36. Tascini C, Gemignani G, Ferranti S et al. Microbiological activity and clinical efficacy of a colistin and rifampicin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004; 16: 282-7.
37. Lynn WA, Golenbock DT. Lipopolysaccharide antagonists. Immunol Today 1992; 13: 271-6.
38. Coyne CP, Moritz JT, Fenwick BW. Inhibition of lipopolysaccharide-induced TNF-α production by semisynthetic polymyxin-B conjugated dextran. Biotechnol Ther 1994; 5: 137-62.
39. Dubor F, Dosne AM, Chedid LA. Effect of polymyxin 8 and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture. Infect Immun 1986; 52: 725-9.
40. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
41. Gamacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111-8.
42. Kasiakou SK, Michalopoulos A, Soteriades ES et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-46.
43. Linden PK, Kusne S, Coley K et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: E154-60.
44. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
45. Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinelobacter baumannii. J Infect 2006; 53: 274-8.
46. Craig WA, Kunin CM. Dynamics of binding and release of the polymyxin antibiotics by tissues. J Pharmacol Exp Ther 1973; 184: 757-65.
47. Wood GC, Swanson JM. Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs 2007; 67: 903-14.